HK56191A - Controlled release combination of carbidopa/levodopa - Google Patents

Controlled release combination of carbidopa/levodopa Download PDF

Info

Publication number
HK56191A
HK56191A HK561/91A HK56191A HK56191A HK 56191 A HK56191 A HK 56191A HK 561/91 A HK561/91 A HK 561/91A HK 56191 A HK56191 A HK 56191A HK 56191 A HK56191 A HK 56191A
Authority
HK
Hong Kong
Prior art keywords
levodopa
water soluble
soluble polymer
carbidopa
cellulose
Prior art date
Application number
HK561/91A
Other languages
German (de)
English (en)
French (fr)
Inventor
Robert E. Dempski
Donald W. Nibbelink
Edward C. Scholtz
Scott A. Reines
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25365017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK56191(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of HK56191A publication Critical patent/HK56191A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK561/91A 1986-06-16 1991-07-18 Controlled release combination of carbidopa/levodopa HK56191A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87498886A 1986-06-16 1986-06-16

Publications (1)

Publication Number Publication Date
HK56191A true HK56191A (en) 1991-07-26

Family

ID=25365017

Family Applications (1)

Application Number Title Priority Date Filing Date
HK561/91A HK56191A (en) 1986-06-16 1991-07-18 Controlled release combination of carbidopa/levodopa

Country Status (17)

Country Link
EP (1) EP0253490B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS6354319A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR950002882B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE58473T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU597670B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1578A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3766308D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK170514B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2018548B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3001102T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK56191A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE60508B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL82823A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ220599A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT85049B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG52191G (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA874233B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US5095054A (en) * 1988-02-03 1992-03-10 Warner-Lambert Company Polymer compositions containing destructurized starch
IL94588A0 (en) * 1989-06-22 1991-04-15 Warner Lambert Co Polymer base blend compositions containing destructurized starch
CA2037178A1 (en) * 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
HU208495B (en) * 1990-06-27 1993-11-29 Alkaloida Vegyeszeti Gyar Process for producing retarde pharmaceutical compositions
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5624960A (en) * 1991-01-23 1997-04-29 Isis Pharma Gmbh Orally administrable drugs for the treatment of central dopamine deficiency conditions
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
DE4341156C2 (de) * 1993-12-02 1997-11-13 Wacker Chemie Gmbh Verwendung von in Wasser redispergierbaren Kunststoffdispersionspulvern als Arzneimittelträger
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US5945424A (en) * 1998-07-31 1999-08-31 G & H Associates, Inc. Treatment of periodic limb movement syndrome
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
RU2365580C2 (ru) * 2004-06-04 2009-08-27 Ксенопорт, Инк. Пролекарства леводопа, композиции на их основе и их применения
WO2007055329A1 (ja) 2005-11-11 2007-05-18 Asahi Kasei Chemicals Corporation 徐放性固形製剤
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
KR101752080B1 (ko) 2007-12-28 2017-06-28 임팩스 라보라토리즈, 인코포레이티드 레보도파 방출 제어형 제제 및 이의 용도
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
CN105120853A (zh) * 2013-03-28 2015-12-02 奥米尼埃克蒂夫健康科技有限公司 类胡萝卜素的脑内神经保护作用
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
WO2015127558A1 (en) * 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
JP2024501235A (ja) 2020-12-22 2024-01-11 アムニール ファーマスーティカルズ エルエルシー レボドパ投薬レジメン
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH468192A (de) * 1964-06-19 1969-02-15 Ciba Geigy Verfahren zur Herstellung von Arzneimitteln in Perlenform
US3632739A (en) * 1969-12-29 1972-01-04 Sandoz Ag Solid sustained release pharmaceutical preparation
JPS58501034A (ja) * 1981-07-08 1983-06-30 キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド プロプラノロ−ル含有高分子拡散マトリツクス
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
ATE58473T1 (de) 1990-12-15
DK302587A (da) 1987-12-17
AU7422887A (en) 1987-12-17
IL82823A (en) 1991-03-10
IL82823A0 (en) 1987-12-20
DK302587D0 (da) 1987-06-15
SG52191G (en) 1991-08-23
DK170514B1 (da) 1995-10-09
IE871559L (en) 1987-12-16
DE3766308D1 (de) 1991-01-03
IE60508B1 (en) 1994-07-27
EP0253490A1 (en) 1988-01-20
NZ220599A (en) 1990-10-26
GR3001102T3 (en) 1992-05-12
JPS6354319A (ja) 1988-03-08
ES2018548B3 (es) 1991-04-16
KR950002882B1 (ko) 1995-03-28
CY1578A (en) 1991-12-20
JPH0445B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-01-06
AU597670B2 (en) 1990-06-07
ZA874233B (en) 1987-12-14
KR880000086A (ko) 1988-03-23
PT85049B (pt) 1990-03-08
EP0253490B1 (en) 1990-11-22
PT85049A (en) 1987-07-01

Similar Documents

Publication Publication Date Title
EP0320051B1 (en) Controlled release combination of carbidopa/levodopa
EP0253490B1 (en) Controlled release combination of carbidopa/levodopa
US4900755A (en) Controlled release combination of carbidopa/levodopa
US4983400A (en) Controlled release combination of carbidopa/levodopa
KR930008954B1 (ko) 약용 서방 기제
US4424235A (en) Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
EP1140034A1 (en) Controlled release formulation of divalproex sodium
AU2010258345A1 (en) Novel pharmaceutical compositions containing pregabalin
US20050106246A1 (en) Controlled release arginine alpha-ketoglutarate
EP1331972B1 (en) Pharmaceutical compositions
JP2007509146A (ja) レボドーパの持続効果のための組成物及び投与形
AU2002213900A1 (en) Pharmaceutical compositions
US20060159751A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa
CA2361496C (en) Ph independent extended release pharmaceutical formulation
WO2007056570A2 (en) Levodopa compositions
AU2003227039B9 (en) Pharmaceutical compositions
BG61200B2 (bg) Контролирано отделяща комбинация от саrвidора/lеvоdора
BG61201B2 (bg) Контролирано отделяща комбинация от саrвidора/lеvоdора
HUE029193T2 (en) Delayed release drug formulations of thiocolchicoside
ZA200300555B (en) Pharmaceutical compositions.

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20070608